866-997-4948(US-Canada Toll Free)

Diabetic Foot Ulcers - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Sep 2013

Category :

Metabolic Disorders

No. of Pages : 113 Pages


Global Markets Directs, \'Diabetic Foot Ulcers Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Foot Ulcers, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Foot Ulcers. Diabetic Foot Ulcers Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Diabetic Foot Ulcers.
  • A review of the Diabetic Foot Ulcers products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Diabetic Foot Ulcers pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Diabetic Foot Ulcers.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Diabetic Foot Ulcers pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Diabetic Foot Ulcers Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Diabetic Foot Ulcers 10
Diabetic Foot Ulcers Therapeutics under Development by Companies 12
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Pre-Clinical Stage Products 18
Comparative Analysis 18
Diabetic Foot Ulcers Therapeutics - Products under Development by Companies 19
Diabetic Foot Ulcers Therapeutics - Products under Investigation by Universities/Institutes 21
Companies Involved in Diabetic Foot Ulcers Therapeutics Development 22
Cardium Therapeutics, Inc. 22
Smith & Nephew Plc 23
GlaxoSmithKline plc 24
medac GmbH 25
Reliance Life Sciences Pvt. Ltd. 26
Nanotherapeutics, Inc. 27
Celgene Corporation 28
Kaken Pharmaceutical Co.,Ltd. 29
Pluristem Therapeutics Inc. 30
CytoTools AG 31
Phage Biotechnology Corporation 32
NovaLead Pharma Pvt. Ltd. 33
BRIDGE BIORESEARCH PLC 34
FirstString Research, Inc. 35
CoDa Therapeutics, Inc. 36
Adocia 37
EyeGene, Inc. 38
Agennix AG 39
OmegaGenesis, Inc. 40
Izun Pharmaceuticals Corporation 41
Praxis Pharmaceuticals Inc. 42
Diabetic Foot Ulcers - Therapeutics Assessment 43
Assessment by Monotherapy Products 43
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
pexiganan acetate - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
GSK-1278863 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
doxycycline - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
GAM-501 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
talactoferrin alfa - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
DermaPro CI-05 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
DermaPro CI-05 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
VLD-02 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Fibroblast Growth Factor-1 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
trafermin - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Biochaperone PDGF-BB - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
WH-1 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
CODA-001 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
DSC-127 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
PLX Cells for Diabetic Foot Ulcer - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
isoniazid - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
PX-070101 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
PPA-904 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
IZN-6D4 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Granexin - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
urokinase - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
AP-102 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Nanorods Topical - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Drug For Diabetic Foot Ulcer - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
SD-101 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Stem Cell Therapy For Diabetic Complications - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
EG-Decorin - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
CSTC-1 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
PDA-002 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
TMBP-3 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Diabetic Foot Ulcers Therapeutics - Drug Profile Updates 90
Diabetic Foot Ulcers Therapeutics - Discontinued Products 103
Diabetic Foot Ulcers Therapeutics - Dormant Products 104
Diabetic Foot Ulcers - Product Development Milestones 105
Featured News & Press Releases 105
Jul 09, 2013: Dipexium Pharmaceuticals Announces the Issuance of a New U.S. Patent for Locilex 105
Jun 18, 2013: Daewoong Pharma Enters Into Contract With Abdi Ibrahim To Export Easyef To Turkey 105
Apr 25, 2013: Derma Sciences Begins Screening Patients In Second Phase III Trial With DSC127 For Healing Diabetic Foot Ulcers 106
Mar 18, 2013: Adocia Announces Phase III Development Program For Treatment Of Diabetic Foot Ulcer 107
Feb 06, 2013: Derma Sciences Initiates Enrollment In DSC127 Phase III Trial For Healing Diabetic Foot Ulcers 107
Jan 16, 2013: DermaTools Biotech Launches Phase III Clinical Trial With DermaPro For Treatment Of Diabetic Foot Syndrome 109
Jan 03, 2013: Dipexium Pharma Receives Special Protocol Assessment From FDA For Phase III Trial In Mildly Infected Diabetic Foot Ulcers With Locilex 109
Dec 21, 2012: CytoTools Announces Issue Of Additional US Patents For DermaPro 110
Oct 22, 2012: Derma Sciences On Track To Begin Phase III Program With DSC127 111
Aug 22, 2012: DermaTools Biotech Successfully Completes Phase IIb Study With DermaPro 111

Appendix 112
Methodology 112
Coverage 112
Secondary Research 112
Primary Research 112
Expert Panel Validation 112
Contact Us 113
Disclaimer 113

List of Table


Number of Products Under Development for Diabetic Foot Ulcers, H2 2013 10
Products under Development for Diabetic Foot Ulcers - Comparative Analysis, H2 2013 11
Number of Products under Development by Companies, H2 2013 13
Number of Products under Development by Companies, H2 2013 (Contd..1) 14
Comparative Analysis by Late Stage Development, H2 2013 15
Comparative Analysis by Mid Clinical Stage Development, H2 2013 16
Comparative Analysis by Early Clinical Stage Development, H2 2013 17
Comparative Analysis by Pre-Clinical Stage Development, H2 2013 18
Products under Development by Companies, H2 2013 19
Products under Development by Companies, H2 2013 (Contd..1) 20
Products under Investigation by Universities/Institutes, H2 2013 21
Cardium Therapeutics, Inc., H2 2013 22
Smith & Nephew Plc, H2 2013 23
GlaxoSmithKline plc, H2 2013 24
medac GmbH, H2 2013 25
Reliance Life Sciences Pvt. Ltd., H2 2013 26
Nanotherapeutics, Inc., H2 2013 27
Celgene Corporation, H2 2013 28
Kaken Pharmaceutical Co.,Ltd., H2 2013 29
Pluristem Therapeutics Inc., H2 2013 30
CytoTools AG, H2 2013 31
Phage Biotechnology Corporation, H2 2013 32
NovaLead Pharma Pvt. Ltd., H2 2013 33
BRIDGE BIORESEARCH PLC, H2 2013 34
FirstString Research, Inc., H2 2013 35
CoDa Therapeutics, Inc., H2 2013 36
Adocia, H2 2013 37
EyeGene, Inc., H2 2013 38
Agennix AG, H2 2013 39
OmegaGenesis, Inc., H2 2013 40
Izun Pharmaceuticals Corporation, H2 2013 41
Praxis Pharmaceuticals Inc., H2 2013 42
Assessment by Monotherapy Products, H2 2013 43
Assessment by Stage and Route of Administration, H2 2013 45
Assessment by Stage and Molecule Type, H2 2013 47
Diabetic Foot Ulcers Therapeutics - Drug Profile Updates 90
Diabetic Foot Ulcers Therapeutics - Discontinued Products 103
Diabetic Foot Ulcers Therapeutics - Dormant Products 104

List of Chart


Number of Products under Development for Diabetic Foot Ulcers, H2 2013 10
Products under Development for Diabetic Foot Ulcers - Comparative Analysis, H2 2013 11
Products under Development by Companies, H2 2013 12
Late Stage Products, H2 2013 15
Mid Clinical Stage Products, H2 2013 16
Early Clinical Stage Products, H2 2013 17
Pre-Clinical Stage Products, H2 2013 18
Assessment by Monotherapy Products, H2 2013 43
Assessment by Route of Administration, H2 2013 44
Assessment by Stage and Route of Administration, H2 2013 45
Assessment by Molecule Type, H2 2013 46
Assessment by Stage and Molecule Type, H2 2013 47

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *